-
Mashup Score: 0GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM - 17 hour(s) ago
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Optimal Thoracic Radiotherapy Dose for Patients With Limited-Stage Small Cell Lung Cancer - 20 hour(s) ago
According to results from a phase 2 trial, 60 Gy in 40 fractions of twice-daily thoracic radiotherapy is preferable to 45 Gy in 30 fractions among patients with limited-stage small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from a phase 2 trial, 60 Gy in 40 fractions of twice-daily thoracic radiotherapy is preferable to 45 Gy in 30 fractions of twice-daily thoracic radiotherapy among patients with LS-SCLC. Learn more: https://t.co/wQw5ALWoTd #medtwitter #onctwitter https://t.co/SXaiB5buND
-
-
Mashup Score: 0Use of Patient-Derived Organoids-Based Testing to Guide Neoadjuvant Treatment for Patients With Locally Advanced Thyroid Cancer - 2 day(s) ago
According to a single arm, phase 2 study, using patient-derived organoids-based testing has potential in guiding neoadjuvant therapy among patients with locally advanced thyroid cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from a phase 2 study, the use of patient-derived organoids and in vitro sensitivity testing shows promise in improving the prognosis for patients with locally advanced thyroid cancer. Learn more: https://t.co/sCKzAFE28L #medtwitter #onctwitter https://t.co/QWCc0jvPAF
-
-
Mashup Score: 0Isatuximab Monotherapy Shows Durability and Efficacy for Heavily Pretreated R/R Multiple Myeloma - 5 day(s) ago
Isatuximab as monotherapy for the treatment of patients with relapsed/refractory multiple myeloma demonstrated improved cancer outcomes and durable responses.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
#Isatuximab as monotherapy for the treatment of patients with relapsed/refractory #MM demonstrated improved cancer outcomes and durable responses. Learn more: https://t.co/DTcId3JPd6 https://t.co/QAz0vCMkv5
-
-
Mashup Score: 0Potential Activity of Afatinib Among Patients With Advanced Solid Tumors With NGR1 Fusions - 5 day(s) ago
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to a small case series of patients enrolled in the phase 2 #TAPUR study, #afatinib showed potential activity among patients with advanced solid tumors harboring #NRG1 fusions. Learn more: https://t.co/izImzOLnXI #medtwitter #onctwitter https://t.co/ehiMvIqdCV
-
-
Mashup Score: 0Disease State Update: Multiple Myeloma - 6 day(s) ago
The Disease State Update: Multiple Myeloma Disease State Hub from Oncology offers relevant news and insights for medical professionals.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
The #IMWG criteria for #MM diagnosis require ≥ 10% clonal plasma cells in the bone marrow or a biopsy-proven #plasmacytoma, along with evidence of end-organ damage or specific biomarkers associated with disease progression. Learn more: https://t.co/JfgbPyBXJn https://t.co/t6sng4G4JA
-
-
Mashup Score: 0FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer - 6 day(s) ago
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Based on results from the #RAMP201 trial, the @US_FDA has approved #avutometinib plus #defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer. Learn more: https://t.co/3fi07lLiE6 #medtwitter #onctwitter #FDAapprovals https://t.co/SCcSq09Z9U
-
-
Mashup Score: 1First-Line TFOX Regimen for Patients With HER2-Negative Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - 6 day(s) ago
According to results from the phase 3 PRODIGE 51-FFCD-GASTFOX trial, the TFOX chemotherapy regimen in the first-line setting improved survival and response outcomes compared to FOLFOX among patients with HER2-negative advanced gastric and gastroesophageal junction adenocarcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to results from the phase 3 PRODIGE 51-FFCD-GASTFOX trial, #TFOX in the first-line setting improved survival and response outcomes compared to #FOLFOX among patients with #HER2-negative advanced GI/GEJ adenocarcinoma. Learn more: https://t.co/JlY7DXHVVU https://t.co/yuwtHG3srk
-
-
Mashup Score: 0
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance prior to development of symptomatic multiple myeloma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
Victor Jimenez-Zepeda, MD, discusses updates in clinical trials for treatment of smoldering #MM and monoclonal #gammopathy of undetermined significance prior to development of symptomatic MM. Learn more: https://t.co/jp3zeFQ4ov https://t.co/iQC2gZUZjj
-
-
Mashup Score: 0Elimination of Axillary Surgery After Neoadjuvant Systemic Therapy for Well-Selected Patients With Invasive Breast Cancer - 7 day(s) ago
According to 5-year follow-up results from a phase 2 study, selective elimination of axillary surgery after neoadjuvant systemic therapy may be possible among patients with HER2-positive or triple-negative invasive breast cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine NewsTweet-
According to 5-year follow-up results from a phase 2 study, selective elimination of axillary surgery after neoadjuvant systemic therapy may be possible among patients with HER2-positive/triple-negative invasive breast cancer. Learn more: https://t.co/BytapVLamx https://t.co/00A8E2RWVQ
-
CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: https://t.co/4l8jmuNkNQ https://t.co/4mX3jYq3eT